A Phase I, Open Label, Study of the Safety, Tolerability and Pharmacokinetics of Pazopanib in Combination With Irinotecan and Cetuximab for the Relapsed or Refractory Metastatic Colorectal Cancer.
Phase of Trial: Phase I
Latest Information Update: 24 Sep 2014
At a glance
- Drugs Pazopanib (Primary) ; Cetuximab; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 16 Mar 2012 Actual end date changed from Mar 2010 to May 2010 as reported by ClinicalTrials.gov.
- 14 Apr 2010 Actual patient number (24) added as reported by ClinicalTrials.gov.
- 14 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.